Suppr超能文献

鉴定可溶性表皮生长因子受体和α5 整合素之间同源性的免疫反应区域。

Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin.

机构信息

Department of Obstetrics, Gynecology, and Reproductive Science, Yale School of Medicine, 310 Cedar Street, New Haven, CT 06520-8063, USA.

出版信息

Biochemistry. 2011 May 24;50(20):4309-21. doi: 10.1021/bi200126j. Epub 2011 Apr 27.

Abstract

Proteins encoded by the epidermal growth factor receptor (EGFR/HER1/ERBB1) gene are being studied as diagnostic, prognostic, and theragnostic biomarkers for numerous human cancers. The clinical application of these tissue/tumor biomarkers has been limited, in part, by discordant results observed for epidermal growth factor receptor (EGFR) expression using different immunological reagents. Previous studies have used EGFR-directed antibodies that cannot distinguish between full-length and soluble EGFR (sEGFR) expression. We have generated and characterized an anti-sEGFR polyclonal antiserum directed against a 31-mer peptide (residues 604-634) located within the unique 78-amino acid carboxy-terminal sequence of sEGFR. Here, we use this antibody to demonstrate that sEGFR is coexpressed with EGFR in a number of carcinoma-derived cell lines. In addition, we show that a second protein of ~140 kDa (p140) also is detected by this antibody. Rigorous biochemical characterization identifies this second protein to be α5-integrin. We show that a 26-amino acid peptide in the calf domain of α5-integrin (residues 710-735) is 35% identical in sequence with a 31-mer carboxy-terminal sEGFR peptide and exhibits an approximately 5-fold lower affinity for anti-sEGFR than the homologous 31-mer sEGFR peptide does. We conclude that the carboxy terminus of sEGFR and the calf-1 domain of α5-integrin share a region of sequence identity, which results in their mutual immunological reactivity with anti-sEGFR. We also demonstrate that anti-sEGFR promotes three-dimensional tissue cohesion and compaction in vitro, further suggesting a functional link between sEGFR and α5-integrin and a role of the calf-1 domain in cell adhesion. These results have implications for the study of both EGFR and sEGFR as cancer biomarkers and also provide new insight into the mechanisms of interaction between cell surface EGFR isoforms and integrins in complex processes such as cell adhesion and survival signaling.

摘要

表皮生长因子受体(EGFR/HER1/ERBB1)编码的蛋白质被作为许多人类癌症的诊断、预后和治疗生物标志物进行研究。这些组织/肿瘤生物标志物的临床应用受到限制,部分原因是使用不同免疫试剂观察到的表皮生长因子受体(EGFR)表达存在不一致的结果。以前的研究使用了不能区分全长和可溶性 EGFR(sEGFR)表达的 EGFR 定向抗体。我们生成并鉴定了一种针对位于 sEGFR 独特的 78 个氨基酸羧基末端序列内的 31 个氨基酸肽(残基 604-634)的抗 sEGFR 多克隆抗血清。在这里,我们使用该抗体证明 sEGFR 与多种癌源性细胞系中的 EGFR 共表达。此外,我们还表明,该抗体还检测到另一种约 140 kDa 的蛋白质(p140)。严格的生化特征鉴定表明,该第二蛋白为α5 整联蛋白。我们表明,α5 整联蛋白的小牛结构域中的 26 个氨基酸肽(残基 710-735)在序列上与 31 个氨基酸羧基末端 sEGFR 肽有 35%的同源性,并且对 sEGFR 的亲和力比对同源 31 个氨基酸 sEGFR 肽低约 5 倍。我们得出结论,sEGFR 的羧基末端和α5 整联蛋白的小牛 1 结构域共享一个序列同源区域,导致它们与抗 sEGFR 相互免疫反应。我们还证明抗 sEGFR 促进体外三维组织凝聚力和紧实度,这进一步表明 sEGFR 和α5 整联蛋白之间存在功能联系,以及小牛 1 结构域在细胞黏附中的作用。这些结果对 EGFR 和 sEGFR 作为癌症生物标志物的研究具有重要意义,也为细胞表面 EGFR 同工型与整联蛋白之间相互作用的机制提供了新的见解,在细胞黏附和存活信号等复杂过程中。

相似文献

1
Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin.
Biochemistry. 2011 May 24;50(20):4309-21. doi: 10.1021/bi200126j. Epub 2011 Apr 27.
4
Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope.
Sci Rep. 2021 Mar 11;11(1):5790. doi: 10.1038/s41598-021-84171-3.
5
Generation and characterization of polyclonal antibodies specific for human p110 sEGFR.
Hybrid Hybridomics. 2002 Jun;21(3):183-9. doi: 10.1089/153685902760173908.
7
Disulfide bond structure of human epidermal growth factor receptor.
J Biol Chem. 1998 May 1;273(18):11150-7. doi: 10.1074/jbc.273.18.11150.
8
Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells.
Exp Cell Res. 2008 Oct 1;314(16):2907-18. doi: 10.1016/j.yexcr.2008.07.013. Epub 2008 Jul 25.

引用本文的文献

1
Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells.
Biochem Biophys Rep. 2022 Aug 19;31:101326. doi: 10.1016/j.bbrep.2022.101326. eCollection 2022 Sep.
2
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
Gynecol Oncol. 2013 Jun;129(3):486-94. doi: 10.1016/j.ygyno.2013.02.019. Epub 2013 Feb 21.
4
EGFR soluble isoforms and their transcripts are expressed in meningiomas.
PLoS One. 2012;7(5):e37204. doi: 10.1371/journal.pone.0037204. Epub 2012 May 18.
5
EGFR/HER-targeted therapeutics in ovarian cancer.
Future Med Chem. 2012 Mar;4(4):447-69. doi: 10.4155/fmc.12.11.

本文引用的文献

1
The epidermal growth factor receptor conundrum.
Cancer. 2011 Jun 1;117(11):2358-60. doi: 10.1002/cncr.25805. Epub 2010 Dec 14.
2
Cancer cells cut homophilic cell adhesion molecules and run.
Cancer Res. 2011 Jan 15;71(2):303-9. doi: 10.1158/0008-5472.CAN-10-2301. Epub 2010 Nov 17.
5
Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.
J Oncol. 2009;2009:526963. doi: 10.1155/2009/526963. Epub 2009 Apr 14.
6
Antibodies specifically targeting a locally misfolded region of tumor associated EGFR.
Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5082-7. doi: 10.1073/pnas.0811559106. Epub 2009 Mar 16.
9
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.
Cancer Res. 2008 Apr 1;68(7):2329-39. doi: 10.1158/0008-5472.CAN-07-5167.
10
Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.
Biochim Biophys Acta. 2008 Apr;1785(2):232-65. doi: 10.1016/j.bbcan.2008.01.001. Epub 2008 Feb 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验